M. Ouali

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T.A. van der Graaf, Jean‐Yves Blay, Sant P. Chawla et al. · The Lancet · 2012 · 2K citations · Full text

Metastatic Soft-tissue Sarcoma, Placebo-controlled Phase 3, Medicine +8

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial

Penella J. Woll, Peter Reichardt, Axel Le Cesne et al. · The Lancet Oncology · 2012 · 572 citations

Surgical Oncology, Soft-tissue Sarcoma, Medicine +8

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes

Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi et al. · The Lancet Oncology · 2011 · 236 citations

Soft-tissue Sarcoma, Pathology, Phase 2 +2

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study

Judith R. Kroep, M. Ouali, Hans Gelderblom et al. · Annals of Oncology · 2010 · 207 citations · Full text

Surgical Oncology, Tumoral Pathology, Tumor Innervation +10

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

Axel Le Cesne, M. Ouali, Michael Leahy et al. · Annals of Oncology · 2014 · 176 citations · Full text

Soft Tissue Sarcoma, Medicine, Pathology +7